Form 4: Supernus CMO's Stock Transactions Post-RSU Vesting

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, reported the acquisition of shares from restricted stock unit vesting and subsequent sale for tax obligations.

Summary

• Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, Inc. (SUPN), reported stock transactions on February 25, 2026.
• He acquired 1,250 shares of Supernus common stock at $0 per share as a result of Restricted Stock Unit (RSU) vesting.
• Concurrently, 1,250 Restricted Stock Units were disposed of as they converted into common stock upon vesting.
• He then disposed of 675 shares of common stock at a price of $50.69 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, his direct beneficial ownership of common stock is 13,341 shares.
• He continues to beneficially own 1,250 Restricted Stock Units, which vest in four equal annual installments, with the first installment occurring on February 23, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event involving RSU vesting and tax-related share sales, which is generally neutral but reflects ongoing executive retention and alignment with shareholder interests.

Positives

• RSU vesting indicates continued compensation and retention of a key executive, aligning their interests with long-term company performance.
• The executive continues to hold a significant number of common shares (13,341) and unvested RSUs (1,250), demonstrating ongoing commitment to the company.

Negatives

• A portion of the vested shares (675) was sold to cover tax obligations, which, while a common practice, represents a reduction in the executive's direct share ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the established vesting schedule for the Restricted Stock Units.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are standard practices for executive compensation in the pharmaceutical industry, aligning executive incentives with long-term company performance while managing tax liabilities.

Comparison to Industry Standards

• This type of transaction, involving RSU vesting and a 'sell-to-cover' for tax purposes, is a common and widely accepted practice across publicly traded companies, including peers in the pharmaceutical sector such as Pfizer, Merck, and Johnson & Johnson.
• It reflects a standard component of executive compensation packages designed to retain talent and align interests with shareholders, rather than indicating a discretionary sale based on market outlook.

Stakeholder Impact

• Shareholders: Minor dilution from RSU issuance (already accounted for in compensation plans), but continued executive alignment through share ownership.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting installments of the remaining 1,250 Restricted Stock Units as per the established schedule.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and a 'sell-to-cover' transaction for tax purposes. It does not provide new fundamental information about the company's performance or strategic direction that would warrant a change in investment thesis. The executive continues to hold a substantial stake, indicating ongoing alignment. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Jonathan Rubin, Chief Medical Officer